Trial Profile
Phase IV Multicenter Open Label Randomized Study of Rebif 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Dec 2018
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms REMAIN
- Sponsors EMD Serono; Merck Serono
- 15 Jan 2011 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
- 15 Jan 2011 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
- 15 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.